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Introduction
During M phase, replicated chromosomes are evenly distributed 
into daughter cells. Inaccurate chromosome segregation can re-
sult in the loss or gain of whole chromosomes, a status referred 
to as aneuploidy (Ricke et al., 2008). Aneuploidy is observed in 
80–90% of human cancers and associated with poor clinical 
outcome, but its role in malignant cell transformation remains 
ambiguous (Holland and Cleveland, 2009; Schvartzman et al., 
2010). To ensure faithful chromosome segregation, eukaryotic 
cells have developed a surveillance system, the mitotic checkpoint, 
which delays anaphase onset until all kinetochores are properly 
attached to microtubules emanating from opposite spindle poles 
(Nezi and Musacchio, 2009). One of the core components   
of this checkpoint is Bub1 (Roberts et al., 1994; Taylor and 
McKeon, 1997). In prophase, this serine/threonine protein kinase 
accumulates at unattached kinetochores where it mediates the 
recruitment of Mad1–Mad2 dimers (Sharp-Baker and Chen, 2001; 
Meraldi and Sorger, 2005; Jeganathan et al., 2007). These 
Mad1–Mad2 dimers produce a diffusible anaphase wait signal 
consisting of protein complexes of Bub3, BubR1, and Mad2 
(Sudakin et al., 2001; Luo et al., 2002; Sironi et al., 2002; Kulukian 
et al., 2009). These complexes bind to and inhibit Cdc20, the 
activating subunit of the anaphase-promoting complex/cyclosome 
(APC/C), an E3 ubiquitin ligase that regulates orderly separation 
of chromosomes by targeting various cell cycle regulators for 
degradation by the 26S proteasome at specific mitotic stages 
(Peters, 2006). Bub1 not only regulates APC/C activity via 
kinetochore recruitment of Mad1–Mad2, but has also been pro-
posed to inhibit APC/C activity directly through phosphorylation 
of Cdc20 (Chung and Chen, 2003; Tang et al., 2004a).
In addition to the Mad proteins, several other mitotic pro-
teins are dependent on Bub1 for efficient recruitment to un-
attached kinetochores, including BubR1, Cenp-E, and Sgo1 
(Sharp-Baker and Chen, 2001; Tang et al., 2004b; Morrow et al., 
2005; Jeganathan et al., 2007; Perera et al., 2007). BubR1 and 
Cenp-E both function in microtubule–kinetochore attachment 
and failure to recruit these proteins at unattached kinetochores 
is known to cause chromosome missegregation (Wood et al., 
1997; Yao et al., 2000; Lampson and Kapoor, 2005; Malureanu 
et al., 2009). Sgo1, on the other hand, acts to maintain centro-
meric cohesion of duplicated chromosomes until bi-orientation 
has been accomplished (Tang et al., 2004b; Boyarchuk et al., 
2007; Kawashima et al., 2010). The current model is that Bub1 
H
igh  expression  of  the  protein  kinase  Bub1  has 
been observed in a variety of human tumors and 
often correlates with poor clinical prognosis, but 
its molecular and cellular consequences and role in tu-
morigenesis  are  unknown.  Here,  we  demonstrate  that 
overexpression of Bub1 in mice leads to near-diploid an-
euploidies and tumor formation. We found that chromo-
some misalignment and lagging are the primary mitotic 
errors  responsible  for  the  observed  aneuploidization. 
High Bub1 levels resulted in aberrant Bub1 kinase activity 
and hyperactivation of Aurora B kinase. When Aurora B 
activity is suppressed, pharmacologically or via BubR1 
overexpression, chromosome segregation errors caused 
by  Bub1  overexpression  are  largely  corrected.  Impor-
tantly, Bub1 transgenic mice overexpressing Bub1 devel-
oped various kinds of spontaneous tumors and showed 
accelerated Myc-induced lymphomagenesis. Our results 
establish that Bub1 has oncogenic properties and suggest 
that Aurora B is a critical target through which over-
expressed Bub1 drives aneuploidization and tumorigenesis.
Bub1 overexpression induces aneuploidy and tumor 
formation through Aurora B kinase hyperactivation
Robin M. Ricke,
1 Karthik B. Jeganathan,
1 and Jan M. van Deursen
1,2
1Department of Pediatric and Adolescent Medicine, 
2Biochemistry and Molecular Biology, Mayo Clinic, Rochester, MN 55905
©  2011  Ricke  et  al.  This  article  is  distributed  under  the  terms  of  an  Attribution–
Noncommercial–Share Alike–No Mirror Sites license for the first six months after the pub-
lication date (see http://www.rupress.org/terms). After six months it is available under a 
Creative Commons License (Attribution–Noncommercial–Share Alike 3.0 Unported license, 
as described at http://creativecommons.org/licenses/by-nc-sa/3.0/).
T
H
E
J
O
U
R
N
A
L
O
F
C
E
L
L
B
I
O
L
O
G
YJCB • VOLUME 193 • NUMBER 6 • 2011   1050
Figure 1.  Bub1 transgenic mice overexpress Bub1 protein in a wide variety of tissues and cell types. (A) Overview of the approach used to generate Bub1 
transgenic mouse strains. (Top) Transgenic mice were generated in which the HA-Bub1 and EGFP transgenes are inactive due to the presence of a floxed 
-geo “STOP” cassette (consisting of -galactosidase-neomycin fusion gene and three tandemly arranged polyadenylation sites) immediately downstream 
of the CAGGS promoter. We bred these transgenics to protamine-Cre transgenic mice (O’Gorman et al., 1997) to excise the STOP cassette in the male 
germline. (Bottom) Breeding of double-transgenic males to wild-type females, yielded offspring in which the CAGGS promoter was juxtaposed with the 
HA-Bub1 and EGFP coding regions in all cells. IRES, internal ribosomal entry site; PA, protamine. (B) Immunoblot analysis of mitotic and asynchronous 
lysates from transgenic and wild-type primary MEFs. Blots were probed for endogenous Bub1 (Bub1), exogenous HA-Bub1 (HA), and GFP (GFP). Actin and 
pH3 were used as loading controls. (C) QRT-PCR for Bub1 transcripts in cycling MEFs of the indicated genotypes. Orange and black arrows mark primer 1051 Oncogenic Bub1 hyperactivates Aurora B kinase • Ricke et al.
spontaneous tumorigenesis and accelerates the development 
of Eµ-Myc–induced lymphomas, firmly establishing that Bub1 
has oncogenic properties.
Results
Generation of Bub1 transgenic mice
To test whether Bub1 has oncogenic properties in vivo, we gen-
erated transgenic mice that express the mouse Bub1 coding se-
quence under control of the CMV early enhancer/chicken -actin 
(CAGGS) promoter (Fig. 1 A). To facilitate transgene detection, 
the Bub1 start codon was replaced by a double hemagglutinin 
(HA) tag sequence. EGFP was coexpressed from an internal 
ribosomal entry site (IRES) to serve as a reporter for HA-Bub1 
expression. Two independent HA-Bub1 transgenic mouse lines 
were obtained. Hereafter we will refer to these lines as Bub1
T85 
(T85) and Bub1
T264 (T264). Mice of both transgenic lines were 
overtly normal and obtained at expected Mendelian frequency 
(unpublished data). The mouse genetic background was mixed 
129SV/E X C57BL/6. Western blot analysis of mouse embry-
onic fibroblasts (MEFs), testis, and ovary from pure C57BL/6 
and 129 wild-type mice confirmed that genetic background 
itself does not vary Bub1 levels (Fig. S1, A and B). Further-
more, there were no differences in karyotypic stability between 
MEFs derived from pure C57BL/6 and 129 mice (Fig. S1 C).
To assess the level of Bub1 overexpression in Bub1
T85 and 
Bub1
T264  mice,  we  first  performed Western  blot  analysis  on 
MEFs derived from these mice. As shown in Fig. 1 B, mitotic ex-
tracts from Bub1
T85 and Bub1
T264 MEFs had substantially higher 
Bub1 protein levels than those from wild-type MEFs. Bub1
T264 
MEFs showed the highest levels of Bub1 overexpression and 
are estimated to contain six- to sevenfold more Bub1 than wild-
type MEFs (Fig. S1 D). Very similar results were obtained with 
cell extracts from asynchronous MEF cultures (Fig. 1 B). Bub1 
expression  levels  were  further  examined  using  quantitative 
(q)RT-PCR. Total (endogenous and transgenic) Bub1 transcript 
levels were 15- and 67-fold increased compared with wild type 
in Bub1
T85 and Bub1
T264 MEFs, respectively (Fig. 1 C). The dif-
ference in transgene expression between the Bub1
T85 and Bub1
T264 
MEFs correlated with EGFP levels in newborn pups (Fig. 1 D). 
Immunolabeling  experiments  with  polyclonal  antibodies  re-
vealed that the level of kinetochore-associated Bub1 is substan-
tially higher in transgenic MEFs than in wild-type MEFs, with 
Bub1
T264 MEFs showing the most profound increase (Fig. 1 E). 
Immunostaining for HA confirmed that HA-Bub1 is properly 
targeted to kinetochores at mitosis onset (not depicted).
The CAGGS promoter cassette that we used is known to 
be ubiquitously active in mice (Novak et al., 2000). To investi-
gate the tissue distribution of transgene expression in Bub1
T85  
phosphorylates threonine 121 of histone H2A at inner centro-
meres (Kawashima et al., 2010), thereby creating a local docking 
site for Sgo1. In turn, Sgo1 then allows for recruitment of PP2A 
to inner centromeres, a protein phosphatase that retains cohe-
sin at centromeres by counteracting Plk1 kinase activity (Tang   
et al., 2006).
Mutations in Bub1 and other mitotic checkpoint genes are 
relatively  rare  in  human  cancers  (Cahill  et  al.,  1998,  1999; 
Gemma et al., 2000; Jaffrey et al., 2000; Sato et al., 2000). On 
the other hand, deregulation of mitotic checkpoint gene expres-
sion seems to occur at much higher incidence. For instance, re-
duced Bub1 expression has been detected in a subset of lung, 
colon, and pancreatic tumors (Shichiri et al., 2002; Hempen et al., 
2003). Mouse models mimicking these reductions are prone to 
aneuploidy and cancer, indicating that Bub1 insufficiency can 
increase cancer risk (Jeganathan et al., 2007; Baker et al., 2009; 
Schliekelman et al., 2009). A far more common event in human 
tumors may be up-regulation of mitotic factors and several stud-
ies have found high Bub1 levels in subsets of breast and gastric 
cancers, and lymphomas (Alizadeh et al., 2000; Shigeishi et al., 
2001; van’t Veer et al., 2002; Grabsch et al., 2003, 2004; Basso 
et al., 2005). Furthermore, independent studies of diverse tumor 
types have identified Bub1 as a gene whose up-regulation corre-
lates with poor clinical prognosis (Sotiriou et al., 2003; Glinsky 
et al., 2005; Nakagawa et al., 2008). Based on these observa-
tions, it is tempting to speculate that there might be a causal re-
lationship between up-regulation of Bub1 and tumorigenesis. 
However, because Bub1 expression is relatively high in prolif-
erating cells compared with quiescent or differentiated cells 
(Perera et al., 2007), increased Bub1 levels may simply repre-
sent an increase in the mitotic index of the tumors compared with 
neighboring tissue. Thus, even though elevated Bub1 gene ex-
pression seems to be a useful prognostic marker for systemic 
progression of certain types of tumors, whether high Bub1 levels 
can drive neoplastic transformation and/or tumor aggressive-
ness has not yet been established. In addition, the molecular 
and physiological consequences of Bub1 up-regulation are 
not known.
To address these key questions, we generated transgenic 
mouse strains that overexpress Bub1 in a wide variety of tis-
sues. Here, we demonstrate that Bub1 overexpression causes 
chromosome misalignment and chromosome lagging result-
ing in near-diploid aneuploidies. We further show that high 
Bub1 levels lead to aberrant phosphorylation of H2A and hyper-
activation of Aurora B kinase. We find that high-fidelity chromo-
some segregation in Bub1 transgenic cells can be restored by 
inhibition of Aurora B, implying that Aurora B is the critical 
target through which overexpressed Bub1 drives aneuploidiza-
tion. Furthermore, we show that Bub1 overexpression drives 
positions for analysis of total (endogenous and exogenous, p1/p2) and endogenous Bub1 (p3/p4), respectively. Data shown are the mean ± SEM (n = 3 
independent cell lines, in triplicate). Values were normalized to TBP. (D) EGFP fluorescence from 1-d-old pups of the indicated genotypes. (E) Representative 
images of wild-type, Bub1
T85, and Bub1
T264 MEFs in prometaphase coimmunostained with anti-Bub1 and anti-centromere antibodies. DNA was visualized 
with Hoechst. Bar, 10 µm. (F) Total Bub1 transcripts in various tissues and cell types from mice of the indicated genotypes (primer pair p1/p2 was used in 
this qRT-PCR analysis). Data shown are the mean ± SEM (n = 3 mice per genotype, in triplicate). Values were normalized to TBP except bone marrow, which 
was normalized to GAPDH. (G) Western blot analysis of extracts of the indicated tissues and cell types for Bub1. Ponceau S served as a loading control.
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Bub1
T85 and Bub1
T264 spreads, respectively, but only in 1–3% of 
wild-type MEFs (Table I). Like wild-type MEFs, metaphase 
spreads of Bub1 transgenic MEFs had no overtly detectable struc-
tural chromosome abnormalities, such as chromosome breaks, 
gaps, and fusions (unpublished data).
Chromosome  counts  on  hepatic  lymphocytes  revealed 
that Bub1
T85 and Bub1
T264 mice already had acquired substantial 
aneuploidy at birth (Table II). An even higher rate of aneuploidy 
was observed in splenic lymphocytes of 6-wk-old Bub1
T85 and 
Bub1
T264 mice, with 31 and 30% of spreads showing aneuploidy, 
respectively. However, no further increases were observed at 5 mo 
of age. PMSCS rates were very low in both Bub1
T85 and Bub1
T264 
lymphocytes (Table II), indicating that Bub1 overexpression does 
not aberrantly affect chromosome cohesin in this cell type. Further-
more, there was no evidence for overt structural chromosome 
instability in Bub1 transgenic lymphocytes (unpublished data).
To assess the mitotic defects that promote aneuploidy due 
to increased Bub1, we monitored chromosome segregation in 
primary transgenic MEFs through an unperturbed mitosis by 
live-cell imaging (van Ree et al., 2010). MEFs were infected 
with a lentivirus encoding mRFP-H2B to permit visualization of 
chromosomes by fluorescence microscopy. The common defect 
in both clones of Bub1 transgenic MEFs was chromosome lag-
ging (Fig. 2, A and B), a defect believed to be caused by the ab-
errant attachment of one kinetochore to both spindle poles, referred 
to as merotelic attachment. Recent studies indicate that such at-
tachments can result from spindle defects caused by centrosome 
and Bub1
T264 mice, we collected a variety of tissues from 6–8-wk-
old mice and extracted RNA for qRT-PCR analysis. As shown in 
Fig. 1 F, most tissues from transgenic mice have substantially 
higher Bub1 transcript levels than corresponding wild-type tis-
sues, although the actual fold increase varied per tissue. Fur-
thermore, although Bub1
T264 transgenic mice expressed higher 
transcript levels than Bub1
T85 mice in several tissues, including 
fat, eye, and small intestine, other tissues, like brain, lung, and 
large intestine, showed quite similar transcript levels. A com-
plementary analysis of the relative expression levels of Bub1 
per organ is presented in Fig. S1 E. Furthermore, Western blot 
analysis of protein extracts from select tissues of wild-type 
and Bub1
T264 mice yielded results that were consistent with those 
obtained by qRT-PCR analysis (Fig. 1 G). Taken together, 
these data indicate that our transgenic mouse lines widely over-
express Bub1.
Bub1 overexpression causes chromosome 
missegregation and near diploid aneuploidy
To determine if Bub1 overexpression affects karyotype stabil-
ity, we performed chromosome counts on metaphase spreads 
of passage 5 (P5) wild-type, Bub1
T85, and Bub1
T264 MEFs. Aneu-
ploidy was observed in 11% of wild-type spreads (Table I). In 
contrast,  aneuploidy  rates  were  substantially  higher  in  both 
Bub1
T85 and Bub1
T264 MEFs, with 21% and 25% of cells showing 
aneuploidy, respectively (Table I). Moreover, we observed pre-
mature sister chromatid separation (PMSCS) in 8 and 12% of 
Table I.  Overexpression of Bub1 in MEFs induces progressive near-diploid aneuploidy
MEF genotype (n) Mitotic figures 
inspected
Aneuploid figures 
(SD)
Karyotypes with indicated chromosome number Mitotic figures with PMSCS 
(SD)
37 38 39 40 41 42 43
% %
WT (3) 150 11 (1) 2 1 5 133 7 2 1 (1)
Bub1
T85 (3) 150 21 (1) 2 1 9 118 15 5 8 (0)
WT (3) 150 11 (1) 5 133 8 3 1 3 (1)
Bub1
T264 (3) 150 25 (1) 1 3 22 113 9 2 12 (1)
Empty spaces mean that there were no karyotypes with the indicated chromosome number. Karyotyping was performed at passage 5.
Table II.  Increasing aneuploidy in lymphocytes from Bub1 transgenic mice
Mouse genotype Age (n) Mitotic figures 
inspected
Aneuploid figures 
(SD)
Karyotypes with indicated chromosome number Mitotic figures with 
PMSCS (SD)
36 37 38 39 40 41 42 43
% %
WT 1 d (3) 150 1 (1) 1 148 1 1 (1)
WT 6 wk (3) 150 2 (2) 2 147 1 1 (2)
WT 5 mo (3) 150 4 (0) 1 2 144 3 1 (1)
Bub1
T85 1 d (3) 150 21 (3) 3 3 5 14 119 5 1 3 (1)
Bub1
T85 6 wk (3) 150 31 (2) 1 8 17 104 13 4 3 3 (1)
Bub1
T85 5 mo (3) 150 35 (6) 4 4 11 23 97 8 3 1 (2)
Bub1
T264 1 d (3) 150 15 (2) 2 1 4 8 127 7 1 0 (0)
Bub1
T264 6 wk (3) 150 30 (3) 4 1 6 15 105 14 5 3 (1)
Bub1
T264 5 mo (3) 150 28 (2) 2 1 8 16 108 12 3 6 (3)
Empty spaces mean that there were no karyotypes with the indicated chromosome number.1053 Oncogenic Bub1 hyperactivates Aurora B kinase • Ricke et al.
assembly, and imply that the chromosome segregation defects 
observed in Bub1 transgenic MEFs are invisible from either 
checkpoint detection or resolution, and not due to rapid ana-
phase onset.
Bub1 overexpression leads to aberrant 
substrate phosphorylation
Selective loss of Bub1 kinase activity in HeLa cells has been 
shown  to  promote  chromosome  misalignment  (Meraldi  and 
Sorger, 2005; Klebig et al., 2009), suggesting that Bub1’s cata-
lytic activity plays a role in microtubule–kinetochore attach-
ment. To test whether Bub1 overexpression leads to aberrant 
catalytic activity, we made use of the recent discovery that Bub1 
kinase phosphorylates histone H2A at threonine 121 in humans 
(Kawashima et al., 2010), a site that is conserved in mouse. In 
wild-type MEFs, pT121-H2A antibody stained kinetochores in 
prophase and prometaphase (Fig. 3 A). This staining remained 
detectable in metaphase but at reduced intensity, and was com-
pletely abolished when cells progressed to anaphase. In pro-
phase, H2A phosphorylation at centromeres was much higher 
in Bub1
T264 MEFs than in wild-type MEFs. Furthermore, in pro-
metaphase, H2A phosphorylation was not only much higher at 
centromeres, but now also occurred along chromosome arms 
(Fig. 3 A). In metaphase, H2A phosphorylation persisted at both 
locations, but was less abundant than in prometaphase. In ana-
phase, no H2A phosphorylation was detectable, similar to wild-
type MEFs (Fig. 3 A). The pattern of H2A phosphorylation in 
Bub1
T85 MEFs mirrored that of Bub1
T264 MEFs, although the 
amount of phosphorylation at centromeres and chromosome arms 
was typically lower than in Bub1
T264 MEFs (Fig. 3, B and C), sug-
gesting that Bub1 overexpression correlates with aberrant Bub1 
catalytic activity. Consistently, by Western blotting we observed 
amplification (Ganem et al., 2009; Silkworth et al., 2009). How-
ever, this mechanism is unlikely to underlie merotely in Bub1 
transgenic MEFs because Bub1
T264 MEFs showed no evidence 
of supernumerary centrosomes when immunostained for cen-
trin 2 (Fig. S2 A).
To determine whether chromosome segregation initiated 
in the presence of unaligned chromosomes would be corrected 
with more time in mitosis, we extended metaphase with the 
addition of MG132. Under these conditions, Bub1
T264 MEFs 
were able to obtain full alignment with kinetics similar to 
wild-type MEFs (Fig. S2 B), raising the possibility that Bub1 
overexpression drives misalignment by accelerating time to 
anaphase onset. To explore this, we followed mRFP-H2B–
positive transgenic and wild-type MEFs through mitosis and 
calculated the duration of each mitotic stage. We found that 
mitotic timing of Bub1
T264 MEFs was comparable to wild-
type and Bub1
T85 MEFs (Fig. S2 C). Alternatively, because 
Bub1 is a key component of the mitotic checkpoint, the chro-
mosome  segregation  defects  observed  in  Bub1  transgenic 
MEFs might be due to mitotic checkpoint weakening. To assay 
for  this,  we  challenged  primary  MEFs  with  two  different 
spindle poisons, nocodazole or taxol, in cells that were in-
fected with lentivirus encoding mRFP-H2B (van Ree et al., 
2010). Importantly, Bub1
T85 and Bub1
T264 MEFs were equally 
able to maintain an arrest in response to nocodazole or taxol, 
similar to wild type (Fig. S2, D and E). Consistent with this, 
we found that kinetochore localization of core mitotic check-
point  proteins  that  accumulate  at  unattached  kinetochores, 
  including BubR1, Cdc20, Mad2, and Cenp-E, was normal in 
Bub1 transgenic MEFs (Fig. S2 F, and unpublished data).   
Together, these data suggested that Bub1 overexpression does 
not interfere with mitotic checkpoint signaling or kinetochore 
Figure 2.  Bub1 overexpression causes chromosome missegregation. (A) Live-cell imaging analysis of chromosome segregation defects in primary MEFs 
with indicated genotypes. (B) Representative images of cells with indicated chromosome missegregation events. Bar, 10 µm.JCB • VOLUME 193 • NUMBER 6 • 2011   1054
Figure 3.  Bub1 overexpression results in aberrant Bub1 substrate phosphorylation. (A) Representative images of wild-type and Bub1
T264 MEFs at the 
indicated stages of mitosis that were immunostained for pT121-H2A and centromeres. DNA was visualized with Hoechst. Bar, 10 µm. (B) Representative 
images of wild-type, Bub1
T85, and Bub1
T264 prometaphases that were immunostained for pT121-H2A and centromeres. DNA was visualized with Hoechst. 
Bar, 10 µm. (C) Quantification of pT121-H2A signal of images from B. Data shown are the average of three independent lines and error bars represent 
SEM. (D) Protein extracts from cycling MEFs of the indicated genotype were blotted and probed for Bub1, pT121-H2A, H2A, and pS10-H3. (E) Representa-
tive images of wild-type, Bub1
T85, and Bub1
T264 prometaphases that were immunostained for centromeres and Sgo1. DNA was visualized with Hoechst. 
Bar, 10 µm. (F) Quantification of Sgo1 signal of images from E. Data are the average of three independent lines and error bars represent SEM.1055 Oncogenic Bub1 hyperactivates Aurora B kinase • Ricke et al.
of T232-phosphorylated Aurora B (Fig. S3 B). Furthermore, 
mitotic Bub1
T264 MEFs had normal amounts of pT232-Aurora B 
at inner centromeric regions (Fig. S3 C). However, we note that 
auto-activation of Aurora B through phosphorylation represents 
an incomplete assessment of total catalytic activity. For exam-
ple, in vitro Aurora B activity is not proportional to phosphory-
lated Aurora B when INCENP is added (Bishop and Schumacher, 
2002; Sessa et al., 2005). Moreover, the amount of pT232-Aurora B 
in vivo was unaffected by haspin siRNA although Aurora B is 
delocalized and results in less centromeric MCAK (Wang et al., 
2010). In addition, Ndc80/Hec1 has recently been shown to 
be de-phosphorylated even in the presence of phosphorylated 
Aurora B (DeLuca et al., 2011).
To determine how Bub1 may affect Aurora B activity, we 
sought to determine whether Bub1 and Aurora B were present 
in a complex. Using coimmunoprecipitation, we found that   
a subset of endogenous Bub1 and Aurora B exists in a com-
plex in wild-type MEFs and that Bub1 overexpression con-
siderably increases the amount of Aurora B that is bound to 
Bub1 (Fig. 4 E). Importantly, we were able to confirm that a 
subset of Bub1 and Aurora B forms a complex in mitotic Hela 
cells (Fig. 4 F).
Bub1-induced Aurora B hyperactivity 
drives chromosome missegregation  
and aneuplody
To test whether Aurora B hyperactivity might drive, at least in 
part, chromosome missegregation in Bub1 overexpression cells, 
we sought to reduce Aurora B kinase activity in Bub1
T85 and 
Bub1
T264 MEFs with small amounts of the Aurora kinase inhibi-
tor ZM447439 (Ditchfield et al., 2003) and then monitor the 
accuracy  of  chromosome  segregation  by  live-cell  imaging.   
At 1 µM ZM447439, cells fail to divide (Ditchfield et al., 2003). 
Titration experiments revealed that wild-type MEFs experience 
mild chromosome missegregation at 2.5 nM ZM447439, indi-
cating that Aurora B function is only partially inhibited at this 
concentration (Fig. 5 A, and unpublished data). Importantly, 
Bub1 kinase activity was unaffected by this degree of Aurora B 
inhibition (Fig. S4 A). Remarkably, at 2.5 nM ZM447439, chro-
mosome lagging decreased from 22% to 1% in Bub1
T85 MEFs 
and from 20% to 1% in Bub1
T264 MEFs (Fig. 5 A). Furthermore, 
chromosome misalignment in Bub1
T264 MEFs decreased from 12% 
to 1% (Fig. 5 A). We would like to point out that 15% of MEFs 
failed to complete mitosis in the presence of 2.5 nM ZM447439, 
independent of genotype (not depicted). To confirm this effect was 
due to Aurora B, we undertook a genetic approach of suppress-
ing Aurora B activity by constitutively overexpressing BubR1 
(Lampson and Kapoor, 2005). High levels of BubR1 did not re-
duce Bub1 levels or activity (Fig. S4, B–D). Importantly, mis-
aligned and lagging chromosomes were suppressed when BubR1 
is overexpressed in Bub1
T264 cells compared with Bub1
T264 alone 
(Fig. 5 A). Similarly, lagging chromosomes were suppressed in 
Bub1
T85 cells co-overexpressing BubR1 (Fig. 5 A).
The corrective effect of BubR1 and treatment with low-
dose ZM447439 was further illustrated by counts of chromo-
some spreads. As shown in Fig. 5 B, high levels of BubR1 
restored aneuploidy rates in both Bub1
T85 and Bub1
T264 MEFs to 
more phosphorylated H2A in an asynchronous population of 
cells in Bub1
T264 cells compared with wild type (Fig. 3 D).
Kawashima et al. (2010) reported H2A phosphorylation 
of the entire chromosome by ectopically expressed Bub1 ki-
nase domain fused to H2B results in relocation of centromere-
associated Sgo1 to chromosome arms. However, we found that 
Sgo1 was properly localized to the centromeric regions of Bub1
T85 
MEFs in prometaphase (Fig. 3 E), when H2A phosphorylation 
was high along chromosome arms (Fig. 3, B and C). Although 
Bub1
T264 MEFs had slightly reduced Sgo1 levels at inner centro-
meric regions (Fig. 3, E and F), there was no detectable increase 
in Sgo1 staining along chromosome arms in any Bub1
T264 cell 
analyzed.  An  inverse  relationship  between  Bub1  and  Sgo1 
abundance at kinetochores has previously been reported (Pouwels 
et al., 2007; Daum et al., 2009), although the exact nature of the 
relationship is currently unclear.
Overexpression of Bub1 results in  
Aurora B hyperactivation
Earlier in vitro studies using Xenopus oocyte extracts have sug-
gested that Bub1 not only phosphorylates H2A but also INCENP, 
although the precise residues targeted by Bub1 remain to be 
identified (Boyarchuk et al., 2007). INCENP is a component of 
the chromosome passenger complex (CPC), which further con-
sists of Aurora B, Borealin, Survivin, and TD-60 (Carmena et al., 
2009). It has been proposed that INCENP binding to Aurora B 
activates basal Aurora B kinase activity, and that phosphoryla-
tion of INCENP by Bub1 induces a feedback loop of additional 
activation (Kang et al., 2001; Bishop and Schumacher, 2002; 
Honda et al., 2003; Sessa et al., 2005; Boyarchuk et al., 2007). 
These findings prompted the hypothesis that Bub1 hyperactivity 
in transgenic MEFs might deregulate the proper control of Aurora B 
kinase activity, an idea that was reinforced by reports demon-
strating that Aurora B contributes to the regulation of kineto-
chore–microtubule attachment (Cimini et al., 2006). Aurora B 
does this, at least in part, through regulating the microtubule-
depolymerizing activity of MCAK and the microtubule-capturing 
activity of Ndc80/Hec1 (Andrews et al., 2004; Cheeseman et al., 
2006; Knowlton et al., 2006).
To explore the role of Aurora B in chromosome missegre-
gation induced by Bub1 overexpression, we first asked whether 
Aurora B kinase activity was aberrantly affected in Bub1 trans-
genic MEFs. As a functional assessment of Aurora B activity, 
we measured the degree of Cenp-A and Knl1 phosphorylation 
using immunofluorescence microscopy (Zeitlin et al., 2001; 
Welburn et al., 2010). In prophase, phosphorylated Cenp-A 
(pCenpA) and phosphorylated Knl1 (pKnl1) staining were both 
significantly higher in Bub1
T264 MEFs than in wild-type MEFs 
(Fig. 4, A–D), indicating that Aurora B might indeed become 
hyperactive upon Bub1 overexpression. 
To begin to address how Bub1 may alter Aurora B activity, 
we monitored Aurora B localization. Targeting of Aurora B to 
inner centromeric regions of mitotic chromosomes was unper-
turbed in Bub1
T264 MEFs (Fig. S3 A), indicating that Bub1 over-
expression does not alter the spatial regulation of Aurora B. Western 
blot analysis of mitotic extracts of wild-type and Bub1
T264 MEFs 
revealed that Bub1-overexpressing cells have normal amounts JCB • VOLUME 193 • NUMBER 6 • 2011   1056
Figure 4.  Aurora B activity is increased in Bub1-overexpressing cells. (A) Representative images of wild-type and Bub1
T264 prophase cells immunostained 
for pCenp-A and centromeres. DNA was visualized with Hoechst. Bar, 10 µm. (B) Quantification of the pCenp-A signal using ImageJ software. Error bars 
represent SEM. *, P < 0.05 vs. wild type (unpaired t test). (C) Representative images of wild-type and Bub1
T264 prophase cells immunostained for pKnl1 
and centromeres. DNA was visualized with Hoechst. Bar, 10 µm. (D) Quantification of the pKnl1 signal using ImageJ software. Error bars represent SEM. 
*, P < 0.05 vs. wild type (unpaired t test). (E) Mitotic extracts of wild-type and Bub1
T264 cells subjected to immunoprecipitation with Bub1, Aurora B, or IgG 
antibodies and analyzed by Western blotting as indicated. (F) Mitotic extracts prepared from taxol-treated HeLa cells subjected to immunoprecipitation with 
Bub1, Aurora B, or IgG antibodies and analyzed by Western blotting as noted.1057 Oncogenic Bub1 hyperactivates Aurora B kinase • Ricke et al.
Bub1 overexpression promotes 
spontaneous tumorigenesis
To address the fundamental question as to whether overexpres-
sion of Bub1 causally predisposes mice to spontaneous tumori-
genesis, cohorts of wild-type, Bub1
T85, and Bub1
T264 mice were 
aged to 12–16 mo and screened for tumors (Fig. 6 A). Overt 
tumors were collected and characterized by routine histopathol-
ogy. Importantly, both transgenic strains had marked increases 
in tumor incidence compared with wild-type littermates (Fig. 6, 
A and B). Specifically, Bub1
T85 and Bub1
T264 mice had a total 
tumor incidence of 62 and 71%, respectively compared with 
27% of wild-type mice, a difference that is highly statistically 
significant. The tumor spectrum of Bub1 transgenic mice was 
broad and included lymphomas, lipomas, sarcomas, and liver 
and skin tumors (Fig. 6, C and D). Bub1 transgenic mice also 
developed lung adenomas, but the incidence of these tumors 
was similar to control mice. A substantial proportion of Bub1 
near wild-type levels. To further validate this idea, we determined 
whether ZM447439 treatment could suppress near-diploid aneu-
ploidy. To do so, we cultured wild-type and Bub1
T264 MEFs 
from passage P0 to P5 in the presence of 2.5 nM ZM447439. 
Treatment of Bub1
T264 MEFs with ZM447439 suppressed near-
diploid  aneuploidy  to  9%,  whereas  aneuploidy  in  wild-type 
MEFs increased to 17% (Fig. 5 B). The observation of 17% 
aneuploidy (but not tetraploidy) in wild-type cells treated 
with 2.5 nM ZM447439 further confirms partial deregula-
tion of Aurora B activity with this concentration of inhibitor. 
Finally, immunostaining of Bub1
T264 cells for pKln1 revealed that 
ZM447439 treatment and BubR1 overexpression each had a sub-
stantial corrective effect on aberrant substrate phosphorylation 
by Aurora B (Fig. S4, E and F; and unpublished data). Collec-
tively, these data suggest that Bub1 overexpression promotes 
hyperactivity of Aurora B, which, in turn, seems to drive chro-
mosome missegregation and aneuploidization.
Figure  5.  Aurora  B  hyperactivation  in  Bub1- 
overexpressing cells drives chromosome missegrega-
tion and aneuploidization. (A) Chromosome segregation 
analysis after treatment with 2.5 nM ZM447439 or 
constitutive co-overexpression of BubR1. The average 
of three independent primary MEFs is shown. Error 
bars represent SEM. (B) Chromosome counts on meta-
phase spreads of P5 wild-type, Bub1
T85, and Bub1
T264 
MEFs  after  treatment  with  2.5  nM  ZM447439  or 
constitutive co-overexpression of BubR1. The average 
of three independent lines is shown and error bars 
represent SEM.JCB • VOLUME 193 • NUMBER 6 • 2011   1058
Figure 6.  Bub1 overexpression promotes spontaneous tumorigenesis. (A) Mouse cohort information. Mice were sacrificed between 12 and 16 mo: the 
average age of the sacrificed animals is indicated per genotype. (B) Spontaneous tumor incidence of mice of the indicated genotypes. *, P < 0.01 vs. 
wild-type mice using Fisher’s exact test. Error bars indicate 95% confidence interval. (C) Tumor spectrum of mice of the indicated genotypes. Error bars 
indicate 95% confidence interval. (D) Histological analysis of selected spontaneous tumors from transgenic mice. Black bar, 100 µm. Red bar, 25 µm.   
Yellow arrow, neoplastic cell; red arrow, normal cell. (E) Interphase FISH for chromosomes 4 and 7 on single cell suspensions of tumors from Bub1 trans-
genic mice. Normal tissues from age-matched wild-type mice were used as controls.1059 Oncogenic Bub1 hyperactivates Aurora B kinase • Ricke et al.
These data demonstrate that Bub1 overexpression synergizes 
with c-Myc in B cell lymphomagenesis, and suggest that Bub1 
plays a role in the pathogenesis of human B cell lymphoma. 
To determine the degree of aneuploidy in lymphomas from 
Eµ-Myc and Eµ-Myc;Bub1
T85 mice, we performed interphase 
FISH on seven independent lymph node tumors per genotype. 
On average, mature tumors from Eµ-Myc;Bub1
T85 mice were 
slightly, but significantly (P < 0.05), more aneuploid for chro-
mosome 4 and chromosome 7 (Fig. 7 D and Fig. S5 B).
Discussion
Bub1 is expressed at high levels in various types of human   
cancers, but whether and how Bub1 overexpression can cause 
neoplastic transformation has remained unknown. Using a trans-
genic approach in mice, we provide evidence that Bub1 has on-
cogenic properties in several mouse tissues. Furthermore, we 
show that Bub1 is consistently overexpressed in human Burkitt’s 
lymphomas and that transgenic Bub1 dramatically decreases 
tumor latency in a mouse model for this lymphoid malignancy. 
Our studies suggest that Bub1 overexpression drives neoplastic 
growth at least in part by promoting chromosome missegrega-
tion. We propose that Bub1 overexpression results in aberrant 
chromosome segregation due to hyperactivation of Aurora B. 
Four  lines  of  evidence  support  this  novel  mechanism.  First, 
Cenp-A,  a  centromere-associated  protein  that  is  targeted  by   
Aurora B kinase in prophase (Zeitlin et al., 2001), and Knl1, a 
key component of the KMN network, were phosphorylated at a 
significantly higher rate in Bub1 transgenic cells than in con-
trols. Phosphorylation at serine 10 of histone H3, another known 
target of Aurora B (Adams et al., 2001; Giet and Glover, 2001), 
occurred at seemingly normal rates in Bub1 transgenic cells 
(unpublished data). However, this is not the first example where 
deregulation of Aurora B differentially affects phosphorylation 
of its targets. For example, Aurora B down-regulation due to 
haspin kinase depletion similarly affected only a limited num-
ber of Aurora B substrates (Wang et al., 2010). The observation 
that not all substrates are equally affected by Bub1-dependent 
Aurora B hyperactivation is also consistent with the notion that 
the activation status of the Aurora B complex may control 
substrate specificity (Musacchio, 2010).
Second, the most common chromosome segregation error 
in Bub1-overexpressing cells is chromosome lagging in ana-
phase (Agarwal et al., 1997), a defect that cannot be detected by 
the mitotic checkpoint and that does not result in mitotic delay. 
Lagging chromosomes occur due to the merotelic attachments 
of chromosomes to the mitotic spindle, which are thought to 
arise frequently in normal cells (Cimini et al., 2003). Aurora B 
functions in the correction of merotelic kinetochore attachments 
(Andrews et al., 2004; Kline-Smith et al., 2004), and its hyper-
activation provides a plausible explanation for the high inci-
dence of lagging chromosomes in Bub1-overexpressing cells. 
Aurora B is thought to correct merotelic attachments by regu-
lating the microtubule-depolymerizing activity of MCAK and 
the microtubule-capturing activity of Ndc80/Hec1 (Cheeseman 
et al., 2006; Knowlton et al., 2006). In addition to lagging 
chromosomes, we observed misaligned chromosomes in cells 
transgenic mice were simultaneously affected with more than one 
tumor type (Fig. 6 C), whereas wild-type mice only had a single 
type of tumor. To assess aneuploidy in Bub1 transgenic tumors, 
we performed interphase FISH on single cell suspensions of 
lymphomas  and  liver  tumors  using  probes  to  chromosomes   
4 and 7 (Baker et al., 2009). Both splenic lymphomas and hepa-
tocellular carcinomas from Bub1 transgenic animals harbored 
significant amounts of aneuploid cells compared with age-
matched wild-type tissue controls (Fig. 6 E), which is consistent 
with the idea that Bub1 overexpression drives tumorigenesis 
through aneuploidization. Together, these results firmly estab-
lish that Bub1 overexpression can drive tumorigenesis in vari-
ous types of tissues/cell types, and that the resulting tumors 
are aneuploid.
Bub1 overexpression in mice accelerates 
Eµ-Myc–induced lymphomagenesis
Gene  expression  profiling  studies  indicate  that  Bub1  is  fre-
quently targeted for up-regulation in diffuse large B cell lym-
phomas (Alizadeh et al., 2000; Basso et al., 2005). To validate 
this observation and to explore whether Bub1 might be over-
expressed in other B cell malignancies as well, we quantitated 
Bub1 transcript levels in a panel of different human primary 
B cell lymphomas and leukemias, including chronic lympho-
cytic leukemia (CLL), diffuse large B cell lymphoma (DLBCL), 
follicular lymphoma (FL), mantle cell lymphoma (MCL), marginal 
zone lymphoma (MZL), and Burkitt’s lymphoma (BL). As a 
control, we used human peripheral B cells from normal donors. 
As shown in Fig. 7 A, Bub1 mRNA was increased (P < 0.05) in 
all cases, except CLL. Particularly high Bub1 transcript levels 
were observed in the BLs. Importantly, this fold increase was 
not observed for two other cell cycle–regulated mitotic check-
point genes, Bub1B and Mad1 (Fig. S5 A). To extend these ob-
servations, we analyzed Bub1 protein levels in the BL cell lines 
Ramos and Raji by Western blotting. Samples were normalized 
for pSer10-H3 to rule out differences in proliferative index. 
Compared with the FL-derived cell line DOHH2, Raji showed 
highly elevated Bub1 levels, whereas in Ramos the increase was 
more modest (Fig. 7 B). Importantly, corresponding increases in 
pH2A and pCenp-A were observed in Raji and Ramos (Fig. 7 B). 
These data are consistent with the notion that increased Bub1 
activity can promote increased Aurora B activity.
Because of the high levels of Bub1 transcript in BLs, a lym-
phoma characterized by overexpression of the c-MYC proto-
  oncogene, we sought to investigate whether Bub1 and c-Myc 
overexpression might cooperate to drive malignant transforma-
tion of B cells. To do so, we intercrossed Eµ-Myc transgenic 
(Harris et al., 1988) and Bub1
T85 mice and established cohorts of 
Eµ-Myc;Bub1
T85, Eµ-Myc mice, and Bub1
T85 transgenic mice 
and monitored them daily for development of ill heath and overt 
tumors. E-Myc single-transgenic animals developed lym-
phoma beginning at 11 wk and had a median survival of 21 wk 
(Fig. 7 C). Strikingly, Eµ-Myc;Bub1
T85 double-transgenic mice 
developed lymphoma much faster; fatal lymphomas developed 
as early as 7 wk and the median survival was only 13 wk. None 
of the Bub1
T85 transgenic mice developed obvious lymphoma 
or any other overt tumors over the 1-yr monitoring period. JCB • VOLUME 193 • NUMBER 6 • 2011   1060
Third, inhibition of Aurora B activity, either pharmaco-
logically with low amounts of ZM447439 or via BubR1 over-
expression, largely corrected chromosome segregation errors 
caused by Bub1 overexpression. Although ZM447439 is a pan 
Aurora kinase inhibitor, at low concentrations, it preferentially 
targets Aurora B. Consistent with increased fidelity of chro-
mosome segregation in Bub1 transgenic cells that express high 
levels of BubR1 we find that these cells show significantly de-
creased aneuploidy rates. We note that, in contrast to Bub1, 
BubR1 overexpression in and of itself does not cause chromo-
some missegregation (unpublished data).
Fourth, we show that a subset of Aurora B is in a complex 
with Bub1 during mitosis and that the abundance of this com-
plex is considerably increased in Bub1 transgenic cells. This raises 
with higher levels of overexpression (Bub1
T264). Interestingly, 
Aurora B has been shown to phosphorylate spatially distinct targets 
to differentially regulate the kinetochore–microtubule  interface 
(Welburn et al., 2010). It is therefore tempting to speculate that 
a broader spectrum of Aurora B targets is deregulated in Bub1
T264 
cells than in Bub1
T85 cells, thereby perhaps explaining why Bub1
T264 
cells have more diverse chromosome segregation errors. Given that 
modification of other CPC members has also been reported to 
affect Aurora B activity (Bishop and Schumacher, 2002; Bolton 
et al., 2002; Honda et al., 2003; Sessa et al., 2005; Jelluma   
et al., 2008) and various Aurora B subcomplexes (Gassmann et al., 
2004),  there  could  exist  many  different  conformations  of   
Aurora B–containing complexes, each with slightly different sub-
strate specificity determined by the status of associated cofactors.
Figure 7.  Bub1 overexpression accelerates Myc-mediated lymphomagenesis. (A) Human Bub1 gene transcript was measured from a panel of 59 primary 
human tumors and normal peripheral B cells using qRT-PCR and normalized to TBP. The difference between lymphomas and normal peripheral B cells was 
statistically significant (P < 0.05) for all groups, except chronic lymphocytic leukemia. (B) Protein extracts from the indicated lymphoma derived cell lines 
were immunoblotted for Bub1, Aurora B, pCenp-A, pT121-H2A, and pS10-H3. (C) Survival curves for E-Myc and E-Myc/Bub1
T85 mice. *, P < 0.05 vs. 
E-Myc mice (log-rank test). (D) Quantification of chromosome 4 and 7 copies in EµMyc and E-Myc/Bub1
T85 B cell lymphoma cells. *, P < 0.05 (unpaired 
t test) FISH signals of 100 cells were per lymphoma. Seven lymphomas were analyzed per genotype. Error bars represent SEM.1061 Oncogenic Bub1 hyperactivates Aurora B kinase • Ricke et al.
Glinsky et al., 2005). We provide a novel mechanism by which 
high Bub1 promotes aneuploidization. Given that losses and gains 
of whole chromosomes can drive tumorigenesis in certain 
genetic contexts (Baker et al., 2009; Holland and Cleveland, 
2009; Baker and van Deursen, 2010; Schvartzman et al., 2010), 
it is reasonable to implicate Bub1-mediated hyperactivation of 
Aurora B in cellular transformation.
Materials and methods
Generation of Bub1 transgenic mice
Bub1 transgenic mice were generated according to previously described 
methods (van Ree et al., 2010, 2011). Bub1 transgenic mice were main-
tained on a mixed 129SV/E × C57BL/6 genetic background. E-Myc 
mice were bred with Bub1
T85 mice to generate cohorts consisting of   
E-Myc, and E-Myc;Bub1
T85 double-transgenic mice. Mice were housed 
in a pathogen-free barrier environment. Mouse protocols were reviewed 
and approved by the Mayo Clinic institutional animal care and use com-
mittee. Mice in tumor susceptibility studies were monitored daily. Moribund 
mice were killed and major organs screened for overt tumors. Tumors were 
processed for histopathology by standard procedures. Prism software was 
used for the generation of tumor-free survival curves and statistical analyses.
Generation and culture of MEFs
Bub1 transgenic MEFs were generated and cultured as described previ-
ously (Baker et al., 2004). MEFs were frozen at P2 or P3 and used for ex-
perimentation between P4 and P6. At least three independently generated 
MEF lines per genotype were used unless otherwise stated. Mitotic MEFs 
were prepared by two methods. Mitotic MEFs were collected after culturing 
asynchronous cells for 4 h in medium containing 100 ng/ml nocodazole 
(Sigma-Aldrich) and harvesting cells by shake-off. Alternatively, cells were 
synchronized in G0 by serum starvation (0.1% FBS) for 12 h and released 
into 10% FBS containing DME. 0.5 µM taxol was then added 12 h after 
release and cells were harvested 18 h after release. Flag-tagged BubR1 
was constitutively expressed using the Z/EG expression vector, similar to 
Bub1 (van Ree et al., 2010).
Cell culture, Western blot analysis, and immunoprecipitation
HeLa cells were cultured in DME supplemented with 10% FCS. Human 
cancer cell lines DOHH2, Ramos, and Raji were cultured in RPMI supple-
mented with 10% FCS. Western blot analysis was performed as described 
previously (van Ree et al., 2010). The following antibodies were used: 
rabbit anti-Bub1 (Jeganathan et al., 2007); 12CA5 or 16B12 (Santa Cruz 
Biotechnology, Inc. and Covance, respectively); pSer10-H3 (Millipore); -actin 
(Sigma-Aldrich);  Aurora  B  (BD);  pT232-Aurora  (Cell  Signaling  Technol-
ogy); GFP (Takara Bio Inc.); pT121-H2A (Kawashima et al., 2010); H2A 
(Abcam); BubR1 (BD); Bub3 (J. van Deursen); and Mad2 (J. van Deursen). 
Immunoprecipitations for Aurora B and Bub1 were performed on mitotic 
cell extracts prepared in RIPA buffer (50 mM Tris, 150 mM NaCl, 0.1% SDS, 
0.5% sodium deoxycholate, 1% NP-40, 1 mM EDTA, 1 mM EGTA, 20 mM 
-glycerophosphate, 20 mM sodium fluoride, and 1 mM sodium vana-
date, plus protease inhibitors). Antibodies for immunoprecipitation were 
Aurora B (BD) and Bub1 (Jeganathan et al., 2007). Mitotic HeLa cells were 
prepared from cells that were serum starved (0.1% FBS) for 12 h and re-
leased into 20% FBS containing DME. After 18 h, 0.5 µM taxol was added 
and cells were harvested 6 h later.
Indirect immunofluorescence and confocal microscopy
Indirect  immunofluorescence  was  performed  as  described  previously 
(Kasper et al., 1999). Cells were plated onto chamber slides and incubated 
for 24 h. Standard fixations for immunostainings were with 1% paraformal-
dehyde for 5 min at room temperature (RT). Primary antibodies, which were 
incubated overnight, were as follows: rabbit anti-Bub1 (Jeganathan et al., 
2007);  human  anti-centromeric  antibody  (Antibodies  Inc.);  rabbit  anti-
Sgo1  (Abcam);  rabbit  anti-pCenp-A  (Millipore);  rabbit  anti-pT121-H2A 
(Active Motif); rabbit anti-pKnl1 (Welburn et al., 2010); rabbit anti-Cdc20 
(Santa Cruz Biotechnology, Inc.); rabbit anti–Mad2 (D. Cleveland, Ludwig 
Institute for Cancer Research, La Jolla, CA); mouse anti-BubR1 (BD); mouse 
anti-Aurora  B  (BD);  rabbit  anti-pThr232-Aurora  (Cell  Signaling  Technol-
ogy); and mouse anti-centrin2 (J. Salisbury, Mayo Clinic, Rochester, MN).   
A laser-scanning microscope (LSM 510 v3.2SP2; Carl Zeiss) with Axiovert 
100M (Carl Zeiss) with a c-Apochromat 100x oil immersion objective was 
the possibility that Bub1 may affect Aurora B activity directly 
or indirectly by modulating the regulatory properties of CPC 
components. One potential mechanism for how Bub1 might 
alter Aurora B activity involves INCENP phosphorylation. 
Xenopus Bub1 has been shown to phosphorylate INCENP in vitro 
(Boyarchuk et al., 2007) and phosphorylation of INCENP at the   
C-terminal TSS motif has been linked to increased Aurora B 
kinase activity (Bishop and Schumacher, 2002; Honda et al., 
2003). Unfortunately, we were unable to directly test this model 
experimentally because the residue(s) of INCENP that are mod-
ified by Bub1 are currently unknown.
Consistent with the idea that Bub1 might exert its onco-
genic effect by targeting Aurora B for deregulation is the obser-
vation that sustained expression of Aurora B in cultured mouse 
mammary gland epithelial cells causes aneuploidy and promotes 
tumor development in a xenograft model (Nguyen et al., 2009). 
It will be important to expand these studies into the oncogenic 
potential of Aurora B, particularly because chromosome lag-
ging due to merotelic attachments is a common trait of human 
cancer cells (Cimini, 2008; Kwon et al., 2008). Given that 
Aurora B activation is highly complex and involves multiple 
mechanisms, it is conceivable that defects in a wide variety of 
mitotic proteins cause Aurora B hyperactivation.
Recent evidence has demonstrated that Bub1 insufficiency 
leads to tumor development (Jeganathan et al., 2007; Baker et al., 
2009). This, together with the transgenic study reported here, 
reveals that optimal Bub1 expression is critical for preventing 
neoplastic growth. Insufficiency and overexpression of Bub1 
both result in whole chromosomal instability and near-diploid 
aneuploidies, although apparently through different mecha-
nisms. Where Bub1 hypomorphism results in weakened check-
point activity (Jeganathan et al., 2007), Bub1 overexpression 
does not seem to impair the checkpoint. This is surprising given 
that Bub1 has been proposed to contribute to checkpoint signaling 
via two mechanisms. First, Bub1 associates with kinetochores 
and this association is required for the kinetochore localization 
of  core  mitotic  checkpoint  proteins  that  produce  the  ana-
phase wait signal, including BubR1, Mad1, Mad2, and Cenp-E 
(Sharp-Baker and Chen, 2001; Morrow et al., 2005; Jeganathan 
et al., 2007; Perera et al., 2007). Second, Bub1 is thought to 
regulate checkpoint activity through inhibitory phosphorylation 
of the APC/C cofactor Cdc20 (Tang et al., 2004a). Earlier trans-
genic models overexpressing Mad2 or Hec1 presented evidence 
of  mitotic  checkpoint  hyperactivation  (Sotillo  et  al.,  2007; 
Diaz-Rodríguez et al., 2008), but this mechanism of deregulat-
ing chromosome segregation does not seem to apply to Bub1 
overexpression. Thus, high Bub1 levels activate an oncogenic 
mechanism that is unique among currently available transgenic 
mouse models. Furthermore, these findings illustrate that it is 
difficult to predict how overexpressed mitotic checkpoint genes 
perturb the chromosome segregation process, and underscores 
the importance of investigating the exact consequences of over-
expression of each checkpoint gene.
In summary, our study demonstrates that Bub1 not only 
has tumor-suppressive but also oncogenic properties, which may 
explain why increased Bub1 expression highly correlates with clin-
ical prognosis in a variety of human cancer types (Glinsky, 2005; JCB • VOLUME 193 • NUMBER 6 • 2011   1062
Bub1, Mad1, and BubR1 gene expression in human B cell malignancies 
and measurements of aneuploidy rates in Eµ-Myc
+ and Eµ-Myc
+;T85 trans-
genic mice. Online supplemental material is available at http://www.jcb 
.org/cgi/content/full/jcb.201012035/DC1.
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used to analyze immunostained cells and to capture representative images. 
For quantification, we used ImageJ software (National Institutes of Health, 
Bethesda, MD). Confocal images were converted to 8-bit grayscale. Cell 
edges were traced using the freehand tool, and the mean pixel intensity 
within the marked area was calculated. The integrated density (in arbitrary 
units), defined as the mean pixel intensity multiplied by the area, was used 
to measure signal strength.
Quantitative RT-PCR
Total RNA was extracted using Trizol and cDNA transcription was per-
formed using random hexamers and SuperScript III reverse transcription 
(Invitrogen). PCR reactions on cDNA from MEFs and mouse tissues were 
performed in triplicate with SYBR green PCR Master Mix using the ABI 
PRISM 7900 Sequence Detection System (Applied Biosystems). All experi-
ments were performed on tissues from at least three animals in each group. 
TATA-binding protein (TBP) was used for normalization using Ct, except 
bone marrow, which was normalized to GAPDH. B and T cells were iso-
lated from spleen using the MACS for CD19
+ cells or pan T cells (Miltenyi 
Biotec), respectively, after red blood cell lysis with ACK buffer (150 mM 
NH4Cl, 10 mM KHCO3, and 0.1 mM EDTA). PCR reactions were per-
formed using the following reaction conditions: 95°C for 5 min, 40 cycles 
of 95°C for 30 s, 60°C for 30 s, and 72°C for 1 min, following with a dis-
sociation stage to confirm a single PCR product. Primer sequences for 
qRT-PCR  were  as  follows:  TotalBub1for  (p1):  5-CATGAGCAGTG-
GGTTAGTGAAGAC-3;  TotalBub1rev  (p2):  5-TTCTCAGAAGCAGGA-
AGGTCCTTG-3; EndoBub1for (p3): 5-GTTTTTTCTCGTCATGGACAAC-3; 
EndoBub1rev (p4): 5-GTCATTACCCGTGTAGCTTTG-3; TBPfor: 5-GGCC-
TCTCAGAAGCATCACTA-3;  TBPrev:  5-GCCAAGCCCTGAGCATAA-3; 
GAPDHfor: 5-TGCACCACACCAACTGCTTAGC-‘3; GAPDHrev: 5-TGGA-
TGCAGGGATGATGTTC-3. We detected endogenous Bub1 transcript with 
primers that anneals to the 5 UTR. PCR reactions on cDNA isolated from 
primary human tumors and normal peripheral B cells were performed 
with Taqman probes (Bub1, 654643; TBP, 4332659; Mad1, 635627; 
Bub1B, 646627) using the ABI PRISM 7900 Sequence Detection System 
(Applied Biosystems).
Karyotype analysis and interphase FISH
Chromosome counts on metaphase spreads from P5 MEFs, splenocytes of 
6-wk- and 5-mo-old mice, and hematopoietic cells in livers of 1-d-old mice 
were performed as described previously (Babu et al., 2003; Baker et al., 
2004). In brief, cells were incubated with colcemid (0.5 µg/ml) for 4 to 6 h, 
swelled with 75 mM KCl, fixed (methanol/glacial acetic acid at 3:1), and 
stained with Giemsa. PMSCS was scored in cells where a majority of the 
sister chromosomes were no longer associated. Single cell suspensions of vari-
ous tissues and tumors were hybridized with probes to chromosomes 4 and 7 
for interphase FISH as described previously (Baker et al., 2009).
Live-cell imaging
For  chromosome  missegregation  analysis,  chromosome  movements  of 
mRFP-H2B–positive  MEFs  progressing  through  an  unchallenged  mitosis 
were followed at interframe intervals of 3 min and mitotic timing for the du-
ration of prophase, prometaphase, metaphase, and anaphase was deter-
mined (Jeganathan et al., 2007; Dawlaty et al., 2008). In brief, MEFs 
were first transduced with a lentivirus encoding an mRFP-tagged H2B to 
allow visualization of chromosomes by fluorescence microscopy. Cells were 
seeded onto 35-mm glass-bottomed culture dishes and 24 h later were 
monitored using an Axio Observer Z1 system (Carl Zeiss) with: CO2 Mod-
ule S, TempModule S, Heating Unit XL S, Pln Apo 63x/1.4 oil DICIII objec-
tive, AxioCam MRm camera, and AxioVision 4.6 software. Nocodazole 
and taxol challenge assays and mitotic timing experiments were performed 
as described previously (Malureanu et al., 2009). At least three indepen-
dent lines per genotype were used. To find a suitable concentration for 
partial inhibition of Aurora B activity, we followed progression of wild-type 
MEFs via live-cell imaging in the presence of various concentrations of ZM 
and determined the percentage of cells with mitotic arrest. We found mi-
totic arrest rates to drop to 15% at 2.5 nM ZM and therefore this concen-
tration was selected for further experimentation.
Online supplemental material
Fig. S1 shows that levels of Bub1 and other mitotic regulators do not vary 
on 129 and C57BL/6 mouse genetic backgrounds. Fig. S2 shows that over-
expression of Bub1 does not disrupt mitotic checkpoint signaling and mitotic 
timing. Fig. S3 shows that Aurora B localization and auto-phosphorylation 
is unaffected by Bub1 overexpression. Fig. S4 shows that treatment of 
Bub1
T264 MEFs with 2.5 nM ZM447439 or co-overexpression of BubR1 
does not diminish Bub1 kinase activity. Fig. S5 provides an analysis of 1063 Oncogenic Bub1 hyperactivates Aurora B kinase • Ricke et al.
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